Next-generation therapy for residual prostate cancer

Raymond A. Clarke, Barry J. Allen

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)

    Abstract

    Prostate cancer claimed an estimated 136,500 lives globally in 2011. Ironically, the best existing treatment strategies provide survival benefits and missed opportunities to further improve outcomes. Prostatectomy provides the greatest survival benefit, albeit the risk of systemic recurrence increases dramatically with extracapsular involvement. To date, further systemic treatment is not generally prescribed for these 'high-risk' patients until such time as advanced disease is diagnosed based on persistent high PSA levels and/or when larger tumors are confirmed by imaging. This recurrent form of the disease is most often terminal. Androgen deprivation therapy (ADT) provides outstanding early control for these patients, which is rather tragic as the early benefits of ADT are lost within 2 years for most men, as the cancer again progresses to an incurable 'late-stage' castration-resistant form of the disease with a median survival of approximately 18 months. We review the potential of targeted α-therapy as an adjuvant with minimal side effects for early-stage high-risk patients to be administered immediately following prostatectomy and/or during ADT.
    Original languageEnglish
    Pages (from-to)1235-1241
    Number of pages7
    JournalImmunotherapy
    Volume5
    Issue number11
    DOIs
    Publication statusPublished - 2013

    Fingerprint

    Dive into the research topics of 'Next-generation therapy for residual prostate cancer'. Together they form a unique fingerprint.

    Cite this